Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients

Abstract

Objectives: To evaluate the prognostic values of microRNAs (miRNAs) in glioblastoma, and to see if there is an association between miRNAs and MGMT promoter methylation status.

Methods: We collected paraffin blocks from resection specimens from 114 glioblastoma patients who had received temozolomide treatment and radiotherapy. Real-time quantitative PCR was performed to determine the expression levels of five miRNAs.

Results: Upregulation of miR 125b-5p, miR 181d-3p, miR 221-3p, miR-222-3p, and miR 224-5p was observed in 13.2%, 5.3%, 12.3%, 32.5%, and 78.9% of the cases, respectively. The expression level of miRNAs was not significantly different in tumors with MGMT promoter methylation vs tumors without such methylation. Upregulation of miR 125b-5p, miR 181d-3p, or miR 221-3p was significantly associated with shorter survival in MGMT-unmethylated glioblastoma patients.

Conclusions: miR 125b-5p, miR 181d-3p, and miR 221-3p are useful in predicting poor prognosis in patients with MGMT-unmethylated glioblastomas.